慢性阻塞性肺病治療藥物市場：按藥物類別、分銷管道分類 - 全球預測 2023-2030 年

預計2023年全球慢性阻塞性肺病藥物市場規模將達203億美元，年複合成長率為7.36%，預計到2030年將以驚人的速度成長至334.4億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球慢性阻塞性肺病藥物市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球慢性阻塞性肺病治療藥物市場規模及預測為何？

2.在預測期內，COVID-19對全球慢性阻塞性肺病治療藥物市場的阻礙因素與影響為何？

3.在預測期內，全球慢性阻塞性肺病治療藥物市場需要投資哪些產品/細分市場/應用/領域？

4.全球慢性阻塞性肺病藥物市場的競爭策略為何？

5. 全球慢性阻塞性肺病藥物市場的技術趨勢和法律規範是什麼？

6.全球慢性阻塞性肺病治療藥物市場主要供應商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入慢性阻塞性肺病藥物全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 世界各地慢性阻塞性肺病（COPD）患者的數量正在增加。
    • 提高對慢性阻塞性肺病的認知和早期診斷
    • 家庭治療的治療設備需求迅速增加
  • 抑制因素
    • 政府實施的嚴格規則和法規
  • 機會
    • 擴大慢性阻塞性肺病治療藥物類別的研究與開發
    • 更多產品已獲得法規批准進入市場
  • 任務
    • 與治療相關的副作用
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 慢性阻塞性肺病治療藥物市場（依藥物類別）

• 支氣管擴張劑
• 組合
• 皮質類固醇
• 黏液動力學
• 4 型磷酸二酯酶抑制劑

第7章 慢性阻塞性肺病治療藥物市場：依通路分類

• 醫院藥房
• 網路藥房
• 零售藥房

第8章 北美和南美慢性阻塞性肺病藥物市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第9章 亞太地區慢性阻塞性肺病治療藥物市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第10章 歐洲、中東和非洲慢性阻塞性肺病藥物市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第11章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第12章上市公司名單

第13章附錄

• 討論指南
• 關於許可證和定價

The Global Chronic Obstructive Pulmonary Disease Therapeutics Market is forecasted to grow significantly, with a projected USD 20.30 billion in 2023 at a CAGR of 7.36% and expected to reach a staggering USD 33.44 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Chronic Obstructive Pulmonary Disease Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Chronic Obstructive Pulmonary Disease Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Class, market is studied across Bronchodilators, Combination, Corticosteroids, Mucokinetics, and Phosphodiesterase Type 4 Inhibitors. The Combination is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Online Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Chronic Obstructive Pulmonary Disease Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Chronic Obstructive Pulmonary Disease Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

6. What is the market share of the leading vendors in the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Chronic Obstructive Pulmonary Disease Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Drug Class, 2022 vs 2030
• 4.3. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Distribution Channel, 2022 vs 2030
• 4.4. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising number of chronic obstructive pulmonary disease (COPD) patients worldwide
    • 5.1.1.2. Grwoth in the awareness and early diagnosis of COPD diseases
    • 5.1.1.3. Surge in demand for home care therapeutic devices
  • 5.1.2. Restraints
    • 5.1.2.1. Strict rules and regulations imposed by the government
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing R&D in drug class of COPD drugs
    • 5.1.3.2. Rise in the number of product launches with the regulatory approval
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effect associated with the treatment
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Drug Class

• 6.1. Introduction
• 6.2. Bronchodilators
• 6.3. Combination
• 6.4. Corticosteroids
• 6.5. Mucokinetics
• 6.6. Phosphodiesterase Type 4 Inhibitors

7. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacies
• 7.3. Online Pharmacies
• 7.4. Retail Pharmacies

8. Americas Chronic Obstructive Pulmonary Disease Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
• FIGURE 6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET DYNAMICS
• FIGURE 8. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOKINETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE TYPE 4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 11. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 22. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 34. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 101. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 102. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET LICENSE & PRICING